122 related articles for article (PubMed ID: 9316874)
1. Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug.
Koller-Lucae SK; Schott H; Schwendener RA
J Pharmacol Exp Ther; 1997 Sep; 282(3):1572-80. PubMed ID: 9316874
[TBL] [Abstract][Full Text] [Related]
2. Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.
Koller-Lucae SK; Schott H; Schwendener RA
Br J Cancer; 1999 Jul; 80(10):1542-9. PubMed ID: 10408395
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
Koller-Lucae SK; Suter MJ; Rentsch KM; Schott H; Schwendener RA
Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
[TBL] [Abstract][Full Text] [Related]
4. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
Schwendener R; Schott H
Methods Enzymol; 2005; 391():58-70. PubMed ID: 15721374
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes.
Horber DH; Ottiger C; Schott H; Schwendener RA
J Pharm Pharmacol; 1995 Apr; 47(4):282-8. PubMed ID: 7791024
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates.
Schott H; Schwendener RA
Anticancer Drug Des; 1996 Sep; 11(6):451-62. PubMed ID: 8836110
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice.
Rentsch KM; Schwendener RA; Schott H; Hänseler E
J Pharm Pharmacol; 1997 Nov; 49(11):1076-81. PubMed ID: 9401941
[TBL] [Abstract][Full Text] [Related]
8. Membrane affinity and metabolism of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine into cultured KB cells.
Tsuruo T; Iida H; Hori K; Tsukagoshi S; Sakurai Y
Cancer Res; 1981 Nov; 41(11 Pt 1):4484-8. PubMed ID: 7306971
[TBL] [Abstract][Full Text] [Related]
9. Sensitive high-performance liquid chromatographic method for the determination of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and erythrocytes.
Rentsch KM; Schwendener RA; Schott H; Hänseler E
J Chromatogr B Biomed Appl; 1995 Nov; 673(2):259-66. PubMed ID: 8611960
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
[TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.
Horber DH; Schott H; Schwendener RA
Br J Cancer; 1995 May; 71(5):957-62. PubMed ID: 7734320
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of liposomal N4octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells.
Schwendener RA; Friedl K; Depenbrock H; Schott H; Hanauske AR
Invest New Drugs; 2001; 19(3):203-10. PubMed ID: 11561676
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcytosi ne.
Horber DH; Cattaneo-Pangrazzi RM; von Ballmoos P; Schott H; Ludwig PS; Eriksson S; Fichtner I; Schwendener RA
J Cancer Res Clin Oncol; 2000 Jun; 126(6):311-9. PubMed ID: 10870640
[TBL] [Abstract][Full Text] [Related]
15. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
[TBL] [Abstract][Full Text] [Related]
16. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent.
Aoshima M; Tsukagoshi S; Sakurai Y; Oh-ishi JI; Ishida T
Cancer Res; 1977 Aug; 37(8 Pt 1):2481-6. PubMed ID: 872077
[TBL] [Abstract][Full Text] [Related]
17. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.
Horber DH; Schott H; Schwendener RA
Cancer Chemother Pharmacol; 1995; 36(6):483-92. PubMed ID: 7554040
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
Yoshida T; Nakamura S; Ohtake S; Ito K; Kobayashi K; Kanno M; Hirai J; Tachimori K; Matsuda T
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1820-4. PubMed ID: 3592717
[TBL] [Abstract][Full Text] [Related]
19. Intracellular distribution of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in blood cells.
Ueda T; Nakamura T; Kagawa D; Yamamoto K; Uchida M; Sasada M; Uchino H
Gan; 1983 Jun; 74(3):445-51. PubMed ID: 6884702
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the conjugate between N4-(4-carboxybutyryl)-1-beta-D-arabinofuranosylcytosine and chitosan as a macromolecular prodrug of 1-beta-D-arabinofuranosylcytosine.
Ichikawa H; Onishi H; Takahata T; Machida Y; Nagai T
Drug Des Discov; 1993; 10(4):343-53. PubMed ID: 8148473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
